B8F Stock Overview
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products.
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.06|
|52 Week High||€3.17|
|52 Week Low||€0.96|
|1 Month Change||-9.79%|
|3 Month Change||-27.15%|
|1 Year Change||-60.74%|
|3 Year Change||-85.20%|
|5 Year Change||-74.28%|
|Change since IPO||-93.09%|
Recent News & Updates
|B8F||DE Pharmaceuticals||DE Market|
Return vs Industry: B8F underperformed the German Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: B8F underperformed the German Market which returned -12.9% over the past year.
|B8F Average Weekly Movement||9.0%|
|Pharmaceuticals Industry Average Movement||6.8%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DE Market||10.6%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: B8F is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: B8F's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria.
Biofrontera Fundamentals Summary
|B8F fundamental statistics|
Is B8F overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|B8F income statement (TTM)|
|Cost of Revenue||€4.12m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.27|
|Net Profit Margin||50.53%|
How did B8F perform over the long term?See historical performance and comparison
Is Biofrontera undervalued compared to its fair value and its price relative to the market?
Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: B8F (€1.06) is trading below our estimate of fair value (€4.18)
Significantly Below Fair Value: B8F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: B8F is good value based on its PE Ratio (4x) compared to the German Pharmaceuticals industry average (23.5x).
PE vs Market: B8F is good value based on its PE Ratio (4x) compared to the German market (17.2x).
Price to Earnings Growth Ratio
PEG Ratio: B8F is good value based on its PEG Ratio (0.2x)
Price to Book Ratio
PB vs Industry: B8F is good value based on its PB Ratio (2x) compared to the DE Pharmaceuticals industry average (2.6x).
How is Biofrontera forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: B8F's forecast earnings growth (16.5% per year) is above the savings rate (-0.05%).
Earnings vs Market: B8F's earnings (16.5% per year) are forecast to grow faster than the German market (7.6% per year).
High Growth Earnings: B8F's earnings are forecast to grow, but not significantly.
Revenue vs Market: B8F's revenue (19.3% per year) is forecast to grow faster than the German market (4.7% per year).
High Growth Revenue: B8F's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if B8F's Return on Equity is forecast to be high in 3 years time
How has Biofrontera performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: B8F has a large one-off gain of €39.7M impacting its March 31 2022 financial results.
Growing Profit Margin: B8F became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: B8F has become profitable over the past 5 years, growing earnings by 27.3% per year.
Accelerating Growth: B8F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: B8F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.9%).
Return on Equity
High ROE: B8F's Return on Equity (35.6%) is considered high.
How is Biofrontera's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: B8F's short term assets (€12.0M) do not cover its short term liabilities (€14.0M).
Long Term Liabilities: B8F's short term assets (€12.0M) exceed its long term liabilities (€1.1M).
Debt to Equity History and Analysis
Debt Level: B8F has more cash than its total debt.
Reducing Debt: B8F's debt to equity ratio has reduced from 68.4% to 1.7% over the past 5 years.
Debt Coverage: B8F's debt is well covered by operating cash flow (6112.2%).
Interest Coverage: Insufficient data to determine if B8F's interest payments on its debt are well covered by EBIT.
What is Biofrontera current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate B8F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate B8F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if B8F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if B8F's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as B8F has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hermann Lubbert (65 yo)
Dr. Prof. Hermann Lubbert, Ph.D. is a Co-Founder of Biofrontera AG and serves as its Chief Executive Officer since 1997 and served as its Chairman of Management Board since 2000 until December 13, 2021. Dr...
CEO Compensation Analysis
Compensation vs Market: Hermann's total compensation ($USD655.13K) is above average for companies of similar size in the German market ($USD404.30K).
Compensation vs Earnings: Hermann's compensation has been consistent with company performance over the past year.
Experienced Management: B8F's management team is considered experienced (3.2 years average tenure).
Experienced Board: B8F's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biofrontera AG's employee growth, exchange listings and data sources
- Name: Biofrontera AG
- Ticker: B8F
- Exchange: XTRA
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €60.120m
- Shares outstanding: 56.72m
- Website: https://www.biofrontera.com
Number of Employees
- Biofrontera AG
- Hemmelrather Weg 201
- North Rhine-Westphalia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.